Strongbridge Biopharma Stock Forecast, Price & News

+0.06 (+2.11 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume674,170 shs
Average Volume1.14 million shs
Market Capitalization$196.01 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Strongbridge Biopharma logo

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.40 out of 5 stars

Medical Sector

726th out of 2,100 stocks

Pharmaceutical Preparations Industry

359th out of 830 stocks

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

Is Strongbridge Biopharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Strongbridge Biopharma stock.
View analyst ratings for Strongbridge Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Strongbridge Biopharma?

Wall Street analysts have given Strongbridge Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Strongbridge Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Strongbridge Biopharma?

Strongbridge Biopharma saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 1,880,000 shares, an increase of 19.7% from the May 13th total of 1,570,000 shares. Based on an average daily volume of 1,350,000 shares, the days-to-cover ratio is presently 1.4 days. Currently, 3.6% of the shares of the stock are short sold.
View Strongbridge Biopharma's Short Interest

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Strongbridge Biopharma

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its quarterly earnings results on Tuesday, May, 11th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. The biotechnology company earned $8.38 million during the quarter, compared to the consensus estimate of $8.22 million. Strongbridge Biopharma had a negative net margin of 136.23% and a negative trailing twelve-month return on equity of 72.48%.
View Strongbridge Biopharma's earnings history

How has Strongbridge Biopharma's stock been impacted by Coronavirus?

Strongbridge Biopharma's stock was trading at $2.32 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SBBP shares have increased by 25.0% and is now trading at $2.90.
View which stocks have been most impacted by COVID-19

What guidance has Strongbridge Biopharma issued on next quarter's earnings?

Strongbridge Biopharma updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $34 million-36 million, compared to the consensus revenue estimate of $36.32 million.

What price target have analysts set for SBBP?

4 analysts have issued 1-year price targets for Strongbridge Biopharma's stock. Their forecasts range from $3.25 to $10.00. On average, they anticipate Strongbridge Biopharma's stock price to reach $6.08 in the next twelve months. This suggests a possible upside of 109.8% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:
  • Mr. John H. Johnson, CEO & Director (Age 63, Pay $1.13M)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 56, Pay $784.11k)
  • Mr. Richard S. Kollender CPA, M.B.A., CPA, Pres & CFO (Age 52)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
  • Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations
  • Mr. Stephen J. Long, Chief Legal Officer & Company Sec. (Age 55)
  • Mr. Brian Conner, Chief Compliance Officer
  • Mr. Dave Bonnell, Sr. VP of Sales
  • Ms. Emily Doyle, Chief HR Officer
  • Mr. Scott L. Wilhoit, Chief Commercial Officer (Age 58)

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (3.45%), BlackRock Inc. (3.25%), Orbimed Advisors LLC (2.58%), Renaissance Technologies LLC (2.29%), Ikarian Capital LLC (1.72%) and Geode Capital Management LLC (1.07%). Company insiders that own Strongbridge Biopharma stock include Associates LLC Cdk and David N Gill.
View institutional ownership trends for Strongbridge Biopharma

Which major investors are selling Strongbridge Biopharma stock?

SBBP stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Ikarian Capital LLC, Renaissance Technologies LLC, Ameriprise Financial Inc., Bank of Montreal Can, Russell Investments Group Ltd., Northern Trust Corp, and First Quadrant L P CA.
View insider buying and selling activity for Strongbridge Biopharma
or view top insider-selling stocks.

Which major investors are buying Strongbridge Biopharma stock?

SBBP stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Geode Capital Management LLC, Worth Venture Partners LLC, BlackRock Inc., Dimensional Fund Advisors LP, Acadian Asset Management LLC, Cubist Systematic Strategies LLC, and Algert Global LLC. Company insiders that have bought Strongbridge Biopharma stock in the last two years include Associates LLC Cdk, and David N Gill.
View insider buying and selling activity for Strongbridge Biopharma
or or view top insider-buying stocks.

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.90.

How much money does Strongbridge Biopharma make?

Strongbridge Biopharma has a market capitalization of $196.01 million and generates $30.73 million in revenue each year. The biotechnology company earns $-45,080,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Strongbridge Biopharma have?

Strongbridge Biopharma employs 72 workers across the globe.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is

Where are Strongbridge Biopharma's headquarters?

Strongbridge Biopharma is headquartered at 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.